Literature DB >> 20870468

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.

Lie Li1, Ming Zhao, Fariba Navid, Keith Pratz, B Doug Smith, Michelle A Rudek, Sharyn D Baker.   

Abstract

A simple and rapid method with high performance liquid chromatography/tandem mass spectrometry is described for the quantitation of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma. A protein precipitation extraction procedure was applied to 50 μL of plasma. Chromatographic separation of the two analytes, and the internal standard [(2)H(3)(13)C]-sorafenib, was achieved on a C(18) analytical column and isocratic flow at 0.3 mL/min for 4 min. Mean within-run and between-run precision for all analytes were <6.9% and accuracy was <5.3%. Calibration curves were linear over the concentration range of 50-10,000 ng/mL for sorafenib and 10-2500 ng/mL for sorafenib N-oxide. This method allows a specific, sensitive, and reliable determination of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma in a single analytical run.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870468      PMCID: PMC2956857          DOI: 10.1016/j.jchromb.2010.08.049

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.

Authors:  Ming Zhao; Michelle A Rudek; Ping He; Frank-Thorsten Hafner; Martin Radtke; John J Wright; B Douglas Smith; Wells A Messersmith; Manuel Hidalgo; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-06-23       Impact factor: 3.205

2.  Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

Authors:  Lokesh Jain; Erin R Gardner; Jürgen Venitz; William Dahut; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2008-01-22       Impact factor: 3.935

Review 3.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Authors:  Scott Wilhelm; Christopher Carter; Mark Lynch; Timothy Lowinger; Jacques Dumas; Roger A Smith; Brian Schwartz; Ronit Simantov; Susan Kelley
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

4.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

5.  Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.

Authors:  Chetan Lathia; John Lettieri; Frank Cihon; Martha Gallentine; Martin Radtke; Pavur Sundaresan
Journal:  Cancer Chemother Pharmacol       Date:  2005-08-25       Impact factor: 3.333

6.  Factors affecting cytochrome P-450 3A activity in cancer patients.

Authors:  Sharyn D Baker; Ron H N van Schaik; Laurent P Rivory; Albert J Ten Tije; Kimberly Dinh; Wilfried J Graveland; Paul W Schenk; Kellie A Charles; Stephen J Clarke; Michael A Carducci; William P McGuire; Fitzroy Dawkins; Hans Gelderblom; Jaap Verweij; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

Review 7.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12

8.  Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice.

Authors:  B Blanchet; B Billemont; J Cramard; A S Benichou; S Chhun; L Harcouet; S Ropert; A Dauphin; F Goldwasser; M Tod
Journal:  J Pharm Biomed Anal       Date:  2009-02-20       Impact factor: 3.935

Review 9.  Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Authors:  Gillian M Keating; Armando Santoro
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

Authors:  A Haouala; B Zanolari; B Rochat; M Montemurro; K Zaman; M A Duchosal; H B Ris; S Leyvraz; N Widmer; L A Decosterd
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-05-13       Impact factor: 3.205

  10 in total
  23 in total

1.  Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Authors:  Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana
Journal:  Clin Cancer Res       Date:  2012-11-08       Impact factor: 12.531

2.  Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Authors:  Hiroto Inaba; Jeffrey E Rubnitz; Elaine Coustan-Smith; Lie Li; Brian D Furmanski; Gerard P Mascara; Kenneth M Heym; Robbin Christensen; Mihaela Onciu; Sheila A Shurtleff; Stanley B Pounds; Ching-Hon Pui; Raul C Ribeiro; Dario Campana; Sharyn D Baker
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

3.  Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.

Authors:  Nilofer Azad; Arvind Dasari; John Arcaroli; Gretchen E Taylor; Daniel A Laheru; Michael A Carducci; Martine McManus; Kevin Quackenbush; John J Wright; Manuel Hidalgo; Luis A Diaz; Ross C Donehower; Ming Zhao; Michelle A Rudek; Wells A Messersmith
Journal:  Invest New Drugs       Date:  2012-05-22       Impact factor: 3.850

4.  Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Authors:  J Kyle Bruner; Hayley S Ma; Li Li; Alice Can Ran Qin; Michelle A Rudek; Richard J Jones; Mark J Levis; Keith W Pratz; Christine A Pratilas; Donald Small
Journal:  Cancer Res       Date:  2017-09-18       Impact factor: 12.701

5.  Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.

Authors:  Maria Cristina Villarroel; Keith W Pratz; Linping Xu; John J Wright; B Douglas Smith; Michelle A Rudek
Journal:  Invest New Drugs       Date:  2011-11-17       Impact factor: 3.850

6.  Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.

Authors:  Qiang Fu; Mingqing Chen; Shuiying Hu; Craig A McElroy; Ron H Mathijssen; Alex Sparreboom; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-05-05       Impact factor: 3.205

7.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

8.  Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.

Authors:  Alfeu Zanotto-Filho; Subapriya Rajamanickam; Eva Loranc; V Pragathi Masamsetti; Aparna Gorthi; July Carolina Romero; Sonal Tonapi; Rosangela Mayer Gonçalves; Robert L Reddick; Raymond Benavides; John Kuhn; Yidong Chen; Alexander J R Bishop
Journal:  Cancer Lett       Date:  2018-03-30       Impact factor: 8.679

9.  Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

Authors:  Aksana Vasilyeva; Selvi Durmus; Lie Li; Els Wagenaar; Shuiying Hu; Alice A Gibson; John C Panetta; Sridhar Mani; Alex Sparreboom; Sharyn D Baker; Alfred H Schinkel
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

10.  Alternative formulations of sorafenib for use in children.

Authors:  Fariba Navid; Robbin Christensen; Hiroto Inaba; Lie Li; Zhaoyuan Chen; Xiangjun Cai; Joshua Regel; Sharyn D Baker
Journal:  Pediatr Blood Cancer       Date:  2013-06-20       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.